Skip to main content

Table 2 Clinical characteristics of the subjects after stopping long-term NA therapy (longitudinal study)

From: Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B

Variable Group CR NCR χ2/Z P
N   26 65   
Gender (M/F)   20/6 55/10 0.758 0.384a
Age (years)   39 (25–60) 35 (18–49) −2.063 0.039b
  HBV DNA (log10 IU/ml) UD UD
ALT (× ULN) 0.488 (0.30–1.00) 0.519 (0.15–1.53) −0.868 0.385b
HBsAg (log10 IU/ml) 2.995 (1.56–4.37) 2.810 (−2.00–4.14) −1.805 0.071b
Anti-HBc (log10 IU/ml) 2.471 (1.51–3.64) 2.718 (1.21–3.86) − 1.162 0.245b
Week 4 HBV DNA (log10 IU/ml) 0.00 (0.00–5.87) 0.00 (0.00–5.92) −3.233 0.001b
ALT (× ULN) 0.543 (0.25–2.08) 0.475 (0.20–1.55) −0.545 0.586b
HBsAg (log10 IU/ml) 2.980 (1.47–4.37) 2.815 (−2.00–4.13) −1.651 0.099b
  Anti-HBc (log10 IU/ml) 2.585 (1.41–3.17) 2.793 (1.21–3.76) −1.296 0.195b
Week 12 HBV DNA (log10 IU/ml) 3.98 (2.41–8.93) 2.39 (0.00–5.71) −5.093 < 0.001b
ALT (× ULN) 0.688 (0.30–18.20) 0.615 (0.15–1.98) −1.456 0.145b
HBsAg (log10 IU/ml) 3.125 (2.12–.75) 2.760 (−1.70–4.14) −2.705 0.007b
Anti-HBc (log10 IU/ml) 3.409 (1.77–4.71) 2.972 (1.21–4.43) −1.555 0.12b
Week 24 HBV DNA (log10 IU/ml) 5.99 (4.30–8.93) 3.110 (0.00–5.73) −5.432 < 0.001b
ALT (× ULN) 1.074 (0.55–8.40) 0.550 (0.16–2.03) −3.929 < 0.001b
HBsAg (log10 IU/ml) 3.575 (2.36–4.81) 2.680 (−2.00–4.19) − 3.756 < 0.001b
Anti-HBc (log10 IU/ml) 3.634 (2.14–4.43) 3.344 (1.30–4.95) −2.068 0.039b
Week 48 HBV DNA (log10 IU/ml) 5.66 (0.00–7.95) 2.880 (0.00–5.87) −2.391 0.017b
ALT (× ULN) 3.200 (1.45–7.90) 0.575 (0.18–1.80) −2.879 0.004b
HBsAg (log10 IU/ml) 3.450 (2.77–3.45) 2.695 (−2.00–4.07) −1.657 0.097b
Anti-HBc (log10 IU/ml) 4.395 (4.13–4.71) 3.378 (1.43–4.97) −3.622 < 0.001b
Start of treatment
HBeAg (Positive:Negative)   17/9 46/19 0.253 0.615
ALT elevation ×ULN   3.53 (0–13.57) 6.20 (0–56.1) −1.538 0.124
HBV DNA log10 IU/ml   6.17(4.07–8.76) 6.33(3.32–9.15) −0.371 0.711
  1. Values are n or median (range)
  2. aChi - squared test
  3. bMann -Whitney U-test
  4. M/F Male or female, CR Off-treatment clinical relapse, NCR Non-clinical relapse group; ALT Alanine aminotransferase, HBsAg Hepatitis B surface antigen, HBV Hepatitis B virus, UD Undetectable (< 20 IU/ml), ULN Upper limit of normal